The purpose of this program is to evaluate the safety, tolerability, and efficacy of the new concomitant and sequential temozolomide regimen in newly diagnosed Glioblastoma patients in a routine care setting.
Participant sampling method: consecutive patient sampling.
Study Type
OBSERVATIONAL
Enrollment
64
Temozolomide will be administered orally at 75 mg/m\^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m\^2 to 200 mg/m\^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
Safety: Number of Adverse Events in the Indicated Categories
Time frame: Weekly during the concomitant treatment phase, and then monthly during the monotherapy phase
Number of Participants Who Discontinued Due to Toxicity
Time frame: Weekly during the concomitant treatment phase, and then monthly during the monotherapy phase
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.